 - The recent AURELIA trial comparing paclitaxel, topotecan or liposomal doxorubicin alone versus combined to bevacizumab after early failure of the first-line with carboplatinpaclitaxel revealed that targeting angiogenesis was beneficial in recurrent platinum-resistant ovarian cancer Pujade-Lauraine, 2012 and 2013, with higher progression-free survival PFS. Thus, the strategy of inhibiting angiogenesis in recurrent resistant-platinum ovarian cancer is very promising. 